TBC1D21

Across TCGA pan-cancer cohorts, TBC1D21 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TBC1D21 data layer compared with 14 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher TBC1D21 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TBC1D21 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

COAD, ESCA, and SKCM are the cancer types where TBC1D21 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	OS	Median	All	0.113	0.803	<.001	48	view →
ESCA	OS	Median	II,III,IV	0.166	0.707	<.001	36	view →
SKCM	OS	Median	II,III,IV	0.609	0.305	.010	8	view →
ACC	OS	Median	All	0.118	0.624	.038	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TBC1D21–COAD (OS)

Open the COAD breakdown →